Contents
Clinical Research Opportunities The State
Oklahoma is home to many renowned clinical research centers, like the Oklahoma Clinical and Translational Science Institute (OCTSI) and Tulsa Cancer Institute. These facilities provide a range of clinical trials for different health issues, treatment modalities, and medical devices.
Clinical trials are designed to provide people with the chance to participate in research studies and provide valuable feedback and data that can benefit the medical community.
Clinical research trials in Oklahoma target a broad spectrum of disease areas. Some of the main diseases studied are cardiovascular diseases, autoimmune disorders, respiratory conditions, pediatric conditions, and cancer.
For example, OU Health Oncologist, Alexandra Ikeguchi, M.D., led a clinical trial that showed a superior treatment sequence for metastatic melanoma. Patients who first took two immunotherapy drugs, followed by targeted therapy medications, experienced a 20% increase in survival over 2 years.
Here is a list of other active and future trials in the area.
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE. Read Less
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/09/2025
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Oklahoma City, Oklahoma
Not set, Oklahoma City, Oklahoma
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Recruiting
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk. Read Less
Gender:
FEMALE
Ages:
Between 50 years and 74 years
Trial Updated:
04/08/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma +1 locations
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
Recruiting
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential.
This study will titrate to tolerance during an initial 3 mo... Read More
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential.
This study will titrate to tolerance during an initial 3 month open label period and then subjects will be randomized to one of 2 arms.
It was determined by statistical analysis that each group must have 105 subjects. All subjects will be enrolled and evaluated for tolerance of NAC between dosages of 2.4 g/day and 4.8 g/day for 3 months. After A 3-month open-label dose-titration phase, SLE subjects will be randomized into 2 groups of 105 subjects either to continue the tolerated dosage of NAC or switched to equal number of placebo capsules. There will be up to seven study visits per SLE subject, including the screening and wash out visits. Visits 2-6 will be scheduled three months apart. The study will last 13 months with the wash-out visit. Each subject will donate approximately 100 ml of blood for biomarker studies at each visit. Healthy control subjects will donate blood at the same time. They will be matched to the SLE subjects by gender, age within 10 years, and ethnicity. Their blood will be used as reference for biomarker assays.
There is a consent form required to participate in the phase II study. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: VA Medical Center, Oklahoma City, Oklahoma
VA Medical Center, Oklahoma City, Oklahoma
Conditions: Systemic Lupus Erythematosus
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Read Less
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma +1 locations
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation. Read Less
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: The University of Oklahoma, Oklahoma City, Oklahoma
The University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Registry Study for Radiation Therapy Outcomes
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2024
Locations: Oklahoma Proton Center, Oklahoma City, Oklahoma
Oklahoma Proton Center, Oklahoma City, Oklahoma
Conditions: Neoplasms
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Recruiting
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygo... Read More
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations.
Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
10/10/2023
Locations: University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901, Oklahoma City, Oklahoma
University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901, Oklahoma City, Oklahoma
Conditions: Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Paid Clinical Trials in Oklahoma
Through paid clinical trials in Oklahoma, volunteers can reap tangible rewards and drive medical progress. Not only do participants get access to cutting-edge technology, medications, or treatment alternatives, but they also get compensated for their role. Oklahoma’s paid clinical trials can ease the financial burdens of volunteers. They can receive monetary and non-monetary compensation. Including reimbursements for travel, gas, and accommodation costs. Some patients may get access to gift cards, vouchers, or free medical care.
Clinical Trials For Healthy Volunteers in Oklahoma
Research teams in Oklahoma have tested many life-changing medical treatments. There is no doubt that healthy volunteers play a valuable role in making the process more efficient and productive for future use.
If you are interested in taking part in healthy clinical trials, check out the list below.
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
Recruiting
the purpose of this experiment is to determine if acute melatonin supplementation alters central and peripheral cardiovascular responses to a cold pressor test at rest and during dynamic exercise.
the purpose of this experiment is to determine if acute melatonin supplementation alters central and peripheral cardiovascular responses to a cold pressor test at rest and during dynamic exercise. Read Less
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
12/05/2024
Locations: Department of Health and Exercise Science, Norman, Oklahoma
Department of Health and Exercise Science, Norman, Oklahoma
Conditions: Healthy
Endothelial Derived Hyperpolarization Factor and Vascular Control
Recruiting
Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-der... Read More
Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA Read Less
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/19/2024
Locations: Department of Health and Exercise Science, Norman, Oklahoma
Department of Health and Exercise Science, Norman, Oklahoma
Conditions: Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults. Read Less
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/30/2025
Locations: Lynn Health Science Institute ( Site 0010), Oklahoma City, Oklahoma
Lynn Health Science Institute ( Site 0010), Oklahoma City, Oklahoma
Conditions: Healthy
Dose-Dependent Effects of Low-Intensity Focused Ultrasound
Recruiting
Low-intensity focused ultrasound (LIFU) has emerged as a tool to modulate the activity of deep brain structures noninvasively and reversibly, with anatomical precision. Following the results of a pilot study in which the investigators observed target engagement when LIFU was applied to the anterior limb of the internal capsule, the investigators now propose to determine the dose-response relationships of LIFU when applied to deep white matter tracts of the human brain. The investigators hope a s... Read More
Low-intensity focused ultrasound (LIFU) has emerged as a tool to modulate the activity of deep brain structures noninvasively and reversibly, with anatomical precision. Following the results of a pilot study in which the investigators observed target engagement when LIFU was applied to the anterior limb of the internal capsule, the investigators now propose to determine the dose-response relationships of LIFU when applied to deep white matter tracts of the human brain. The investigators hope a successful study will be rapidly translatable into clinical trials seeking to understand mechanistic brain circuit-symptom relationships in major psychiatric disorders. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Healthy Controls
Medical Discoveries and Innovation in Oklahoma
In the U.S., the rise of medical schools started in the mid-19th century. Certifications and doctors developed slowly. Eventually, bona fide experts became a key component of the OK medical history.
Since then, Oklahoma research centers have made remarkable discoveries that helped create life-saving treatments for various diseases. Here, generations of inventors have expanded their knowledge and resources to commercialize a wide range of products.
Some of the most notable advancements in the region include:
- Geroscience Research: Oklahoma is known for its research studies on the treatment of age-related brain diseases. The state’s contribution helped shed light on complex problems like osteoporosis.
- Cancer Research: Oklahoma Cancer Specialists and Research Institute (OCSRI) is at the forefront of clinical trials for new cancer treatments. Almost all of the clinical advances in the field come from contributions from OK scientists.
- Respiratory disease research: The NIH granted $11.1 million to a biomedical research facility at Oklahoma State University to develop drugs and vaccines that limit transmission, avoid infection, treat lung injuries, and avert similar complications.
Why Oklahoma Is A Great Place For Clinical Research
The Oklahoma population is quite diverse. This makes it a suitable choice for clinical research. Data indicates that 63.8% of the population is White, 11.7% is Hispanic, 8.6% is American Indian, 7.4% is Black, 5.9% is multiracial, and 2.4% is Asian.